| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED OCTOBER 2016. Refer to TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | aflibercept (Eylea®) | |
| Formulation | 40 mg/ml solution for injection | |
| Reference number | 1721 | |
| Indication | Treatment of adults with visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO) |
|
| Company | Bayer Healthcare Pharmaceuticals | |
| BNF chapter | Eye | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 26/06/2015 | |
| Date of issue | 30/06/2015 | |
| NICE guidance | ||